Alexander D. Fuld

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer”.

Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer

JAMA Oncology(2023)10.1001/jamaoncol.2023.4025

N/A

1.1DataRank · unranked

48 citations

Zhonglin Hao, Liza C. Villaruz, Jun Zhang, Jimmy Ruiz, W. Jeffrey Petty +33 more

Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous nonsmall lung cancer (ETCTN 10313)

The Oncologist(2025)10.1093/oncolo/oyaf373

N/A

0.109DataRank · unranked

1 citations

Benjamin Schluger, Hong Wang, James Ohr, Daniel P. Petro, Alexander D. Fuld +10 more

A pragmatic, single-arm clinical trial of a dose modification algorithm for preventing cytopenia-related delays during FOLFOX chemotherapy

Supportive Care in Cancer(2025)10.1007/s00520-025-09784-0

N/A

0DataRank · unranked

0 citations

Tor D. Tosteson, Kathryn Cunningham Hourdequin, Gregory H. Ripple, Alexander D. Fuld, Konstantin H. Dragnev +9 more